ATE476441T1 - Wirksame lna-oligonukleotide zur inhibierung von hif-1a - Google Patents

Wirksame lna-oligonukleotide zur inhibierung von hif-1a

Info

Publication number
ATE476441T1
ATE476441T1 AT05800760T AT05800760T ATE476441T1 AT E476441 T1 ATE476441 T1 AT E476441T1 AT 05800760 T AT05800760 T AT 05800760T AT 05800760 T AT05800760 T AT 05800760T AT E476441 T1 ATE476441 T1 AT E476441T1
Authority
AT
Austria
Prior art keywords
lna
deoxynucleotide
designates
lna nucleotide
subscript
Prior art date
Application number
AT05800760T
Other languages
English (en)
Inventor
Frank Winther Rasmussen
Majken Westergaard
Henrik Frydenlund Hansen
Charlotte Albek Thrue
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36177326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE476441(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of ATE476441T1 publication Critical patent/ATE476441T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05800760T 2004-11-09 2005-11-09 Wirksame lna-oligonukleotide zur inhibierung von hif-1a ATE476441T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62656304P 2004-11-09 2004-11-09
US64718605P 2005-01-25 2005-01-25
US69972105P 2005-07-15 2005-07-15
US72462105P 2005-10-07 2005-10-07
PCT/DK2005/000721 WO2006050734A2 (en) 2004-11-09 2005-11-09 Potent lna oligonucleotides for the inhibition of hif-1a expression

Publications (1)

Publication Number Publication Date
ATE476441T1 true ATE476441T1 (de) 2010-08-15

Family

ID=36177326

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05800760T ATE476441T1 (de) 2004-11-09 2005-11-09 Wirksame lna-oligonukleotide zur inhibierung von hif-1a

Country Status (16)

Country Link
US (3) US7589190B2 (de)
EP (1) EP1833840B9 (de)
JP (3) JP4825807B2 (de)
KR (1) KR101176245B1 (de)
AT (1) ATE476441T1 (de)
AU (1) AU2005304112B2 (de)
BR (1) BRPI0515726A8 (de)
CA (1) CA2587173C (de)
DE (1) DE602005022768D1 (de)
DK (1) DK1833840T3 (de)
EA (1) EA014097B1 (de)
IL (1) IL183054A0 (de)
MX (1) MX2007005558A (de)
NO (1) NO341878B1 (de)
NZ (1) NZ555644A (de)
WO (1) WO2006050734A2 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2284269T3 (en) 2002-11-18 2017-10-23 Roche Innovation Ct Copenhagen As Antisense design
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
EP2141234B1 (de) 2003-03-21 2016-04-27 Roche Innovation Center Copenhagen A/S Analoga kurzer interferierender RNA (SIRNA)
WO2005073378A1 (en) * 2004-01-30 2005-08-11 Santaris Pharma A/S MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
DK1833840T3 (da) * 2004-11-09 2010-10-18 Santaris Pharma As Micromirs
WO2007087113A2 (en) 2005-12-28 2007-08-02 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
EP1984382B1 (de) * 2006-01-27 2012-08-15 Santaris Pharma A/S Lna-modifizierte phosphorothiolierte oligonukleotide
CA2644347C (en) 2006-03-23 2017-05-30 Santaris Pharma A/S Small internally segmented interfering rna
WO2007143315A2 (en) 2006-05-05 2007-12-13 Isis Pharmaceutical, Inc. Compounds and methods for modulating expression of pcsk9
AU2007296055A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
EP2149605B1 (de) 2007-03-22 2013-07-03 Santaris Pharma A/S Kurze RNA Antagonistverbindungen zur Modulation von Ziel mRNA
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
CN101868251B (zh) * 2007-08-06 2012-10-10 千寿制药株式会社 含有HIF-1α和HIF-2α表达抑制物质的药物
EP2548962B1 (de) * 2007-09-19 2016-01-13 Applied Biosystems, LLC Sirna-sequenz-unabhängige Modifikationsformate zur Verringerung von das Ziel verfehlenden phänotypischen Effekten bei RNAI und stabilisierte Formen davon
WO2009043759A2 (en) * 2007-10-04 2009-04-09 Santaris Pharma A/S Short rna antagonist compounds for the modulation of hif1alpha
US8153606B2 (en) 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
MX2011005910A (es) 2008-12-04 2011-06-17 Opko Curna Llc Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina.
CN102361985B (zh) 2008-12-04 2017-06-20 库尔纳公司 通过抑制肿瘤抑制基因的天然反义转录物治疗肿瘤抑制基因相关性疾病
JP5971948B2 (ja) 2008-12-04 2016-08-17 クルナ・インコーポレーテッド Ｖｅｇｆに対する天然アンチセンス転写物の抑制による血管内皮増殖因子（ｖｅｇｆ）関連疾患の治療
PT2396038E (pt) 2009-02-12 2016-02-19 Curna Inc Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf
JP6116242B2 (ja) 2009-03-16 2017-04-19 クルナ・インコーポレーテッド 核因子（赤血球由来２）様２（ｎｒｆ２）に対する天然アンチセンス転写物の抑制によるｎｒｆ２関連疾患の治療
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
KR101835889B1 (ko) 2009-05-06 2018-03-08 큐알엔에이, 인크. 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료
JP6250930B2 (ja) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド トリステトラプロリン（ｔｔｐ）に対する天然アンチセンス転写物の抑制によるｔｔｐ関連疾患の治療
CA2761248C (en) 2009-05-08 2023-03-14 Joseph Collard Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
NO2432881T3 (de) 2009-05-18 2018-04-14
CN102549158B (zh) 2009-05-22 2017-09-26 库尔纳公司 通过抑制针对转录因子e3(tfe3)的天然反义转录物来治疗tfe3和胰岛素受体底物蛋白2(irs2)相关的疾病
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CN102612560B (zh) 2009-06-16 2017-10-17 库尔纳公司 通过抑制针对对氧磷酶1(pon1)的天然反义转录物来治疗pon1相关的疾病
CN102695797B (zh) 2009-06-16 2018-05-25 库尔纳公司 通过抑制针对胶原基因的天然反义转录物来治疗胶原基因相关的疾病
ES2618894T3 (es) 2009-06-24 2017-06-22 Curna, Inc. Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
JP5907866B2 (ja) 2009-06-26 2016-04-26 クルナ・インコーポレーテッド ダウン症候群遺伝子に対する天然アンチセンス転写物の抑制によるダウン症候群遺伝子関連疾患の治療
KR101801407B1 (ko) 2009-07-24 2017-11-24 큐알엔에이, 인크. 시르투인 (ｓｉｒｔ)에 대한 천연 안티센스 전사체의 억제에 의한 시르투인 관련된 질환의 치료
ES2585360T3 (es) 2009-08-05 2016-10-05 Curna, Inc. Tratamiento de enfermedades relacionadas con un gen de la insulina (INS) por inhibición de la transcripción antisentido natural en un gen de la insulina (INS)
JP6189594B2 (ja) 2009-08-11 2017-08-30 クルナ・インコーポレーテッド アディポネクチン（ａｄｉｐｏｑ）に対する天然アンチセンス転写物の抑制によるアディポネクチン（ａｄｉｐｏｑ）関連疾患の治療
KR101805213B1 (ko) 2009-08-21 2017-12-06 큐알엔에이, 인크. Ｃｈｉｐ에 대한 천연 안티센스 전사체의 억제에 의한 “ｈｓｐ70-상호작용 단백질(ｃｈｉｐ)의 ｃ-말단” 관련된 질환의 치료
CN102482671B (zh) 2009-08-25 2017-12-01 库尔纳公司 通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
DK2480669T3 (en) 2009-09-25 2018-02-12 Curna Inc TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY
AR078770A1 (es) 2009-10-27 2011-11-30 Elara Pharmaceuticals Gmbh Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
ES2661813T3 (es) 2009-12-16 2018-04-04 Curna, Inc. Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
KR101891352B1 (ko) 2009-12-23 2018-08-24 큐알엔에이, 인크. 간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
KR101793753B1 (ko) 2009-12-23 2017-11-03 큐알엔에이, 인크. 커플링방지 단백질 ２(ｕｃｐ２)에 대한 천연 안티센스 전사체의 저해에 의한 ｕｃｐ２ 관련 질환의 치료
RU2611186C2 (ru) 2009-12-29 2017-02-21 Курна, Инк. ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С ОПУХОЛЕВЫМ БЕЛКОМ 63 (р63), ПУТЕМ ИНГИБИРОВАНИЯ ПРИРОДНОГО АНТИСМЫСЛОВОГО ТРАНСКРИПТА К р63
KR101838305B1 (ko) 2009-12-29 2018-03-13 큐알엔에이, 인크. ＮＲＦ1(Ｎｕｃｌｅａｒ Ｒｅｓｐｉｒａｔｏｒｙ Ｆａｃｔｏｒ 1)에 대한 천연 안티센스 전사체의 억제에 의한 핵 호흡 인자 1 관련된 질환의 치료
CN102791862B (zh) 2009-12-31 2017-04-05 库尔纳公司 通过抑制胰岛素受体底物2(irs2)和转录因子e3(tfe3)的天然反义转录物而治疗irs2相关疾病
NO2521784T3 (de) 2010-01-04 2018-05-05
JP5963680B2 (ja) 2010-01-06 2016-08-03 カッパーアールエヌエー，インコーポレイテッド 膵臓発生遺伝子に対する天然アンチセンス転写物の阻害による膵臓発生遺伝子疾患の治療
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
DK2529015T3 (en) 2010-01-25 2018-02-26 Curna Inc TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1
CN102844435B (zh) 2010-02-22 2017-05-10 库尔纳公司 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
RU2612884C2 (ru) 2010-04-02 2017-03-13 Курна, Инк. Лечение заболеваний, связанных с колониестимулирующим фактором 3 (csf3), путем ингибирования природного антисмыслового транскрипта k csf3
JP5978203B2 (ja) 2010-04-09 2016-08-24 カッパーアールエヌエー，インコーポレイテッド Ｆｇｆ２１に対する天然アンチセンス転写物の阻害による線維芽細胞増殖因子（ｆｇｆ２１）線維芽細胞増殖因子ｆｇｆ２１）関連疾患の治療
CN107988228B (zh) 2010-05-03 2022-01-25 库尔纳公司 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
CN102947451B (zh) 2010-05-26 2017-09-22 库尔纳公司 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病
CN102971423B (zh) 2010-05-26 2018-01-26 库尔纳公司 通过抑制蛋氨酸硫氧化物还原酶a(msra)的天然反义转录物而治疗msra相关疾病
JP6109069B2 (ja) * 2010-06-04 2017-04-05 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ｍｉＲ−３７８による代謝調節
US9771579B2 (en) 2010-06-23 2017-09-26 Curna, Inc. Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
DK2593547T3 (en) 2010-07-14 2018-02-26 Curna Inc Treatment of Discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
US8987225B2 (en) 2010-11-23 2015-03-24 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
WO2012082765A2 (en) 2010-12-16 2012-06-21 The United State Of America. As Represented By The Secretary Department Of Health And Human Services Methods for decreasing body weight and treating diabetes
EP2673361B1 (de) 2011-02-08 2016-04-13 Ionis Pharmaceuticals, Inc. Oligomere verbindungen mit bicyclischen nukleotiden und ihre verwendung
KR102043422B1 (ko) 2011-06-09 2019-11-11 큐알엔에이, 인크. 프라탁신 (fxn)에 대한 자연 안티센스 전사체의 저해에 의한 프라탁신 (fxn) 관련된 질환의 치료
KR101991980B1 (ko) 2011-09-06 2019-06-21 큐알엔에이, 인크. 소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
CN110438125A (zh) 2012-03-15 2019-11-12 科纳公司 通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
SG10201804331TA (en) * 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
EP3003392B1 (de) 2013-06-04 2019-10-23 President and Fellows of Harvard College Rna-geführte transkriptionsregulation
EP3472347B1 (de) 2016-06-17 2023-01-04 F. Hoffmann-La Roche AG In-vitro-screeningtests für nephrotoxizität
US11105794B2 (en) * 2016-06-17 2021-08-31 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
WO2018160772A1 (en) 2017-02-28 2018-09-07 The United State Of America, As Represented By The Secretary, Department Of Health & Human Services Method of treating obesity, insulin resistance, non-alcoholic fatty liver disease including non-alcoholic steatohepatitis

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5278324A (en) 1990-08-28 1994-01-11 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
MX9102128A (es) 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US6030954A (en) * 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US5250683A (en) 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
US5227400A (en) 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
FR2688518B1 (fr) 1992-03-13 1994-05-06 Rhone Poulenc Rorer Sa Procede de preparation de derives du taxane.
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5254580A (en) 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
US6770748B2 (en) * 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
EP2341058A3 (de) 1997-09-12 2011-11-23 Exiqon A/S Oligonukleotidanaloga
US6238921B1 (en) * 1998-03-26 2001-05-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human mdm2 expression
EP1064378A2 (de) 1998-03-27 2001-01-03 The Board Of Trustees Of The Leland Stanford Junior University Durch hypoxie-induzierbare humane gene, proteine und deren verwendung
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
AU777049B2 (en) 1999-03-18 2004-09-30 Qiagen Gmbh Xylo-LNA analogues
EP1163250B1 (de) 1999-03-24 2006-07-12 Exiqon A/S Verbesserte synthese für ¬2.2.1.|bicyclo-nukleoside
US6350868B1 (en) 1999-04-26 2002-02-26 University Of North Carolina At Chapel Hill Antisense human fucosyltransferase sequences and methods of use thereof
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
AU5717400A (en) 1999-06-14 2001-01-02 Cancer Research Ventures Limited Cancer therapy
WO2000078341A1 (en) 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
US6168950B1 (en) * 1999-07-23 2001-01-02 Isis Pharmaceuticals, Inc. Antisense modulation of MEKK1 expression
WO2001025248A2 (en) 1999-10-04 2001-04-12 Exiqon A/S Design of high affinity rnase h recruiting oligonucleotide
US6706505B1 (en) * 2000-03-08 2004-03-16 Amgen Inc Human E3α ubiquitin ligase family
PL366039A1 (en) * 2000-09-02 2005-01-24 Grunenthal Gmbh Antisense oligonucleotides against vr1
JP4413493B2 (ja) 2000-10-04 2010-02-10 サンタリス ファーマ アー／エス プリンｌｎａ類似体の改善された合成方法
AU2002231223A1 (en) 2000-10-26 2002-05-06 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
AU2002317437A1 (en) 2001-05-18 2002-12-03 Cureon A/S Therapeutic uses of lna-modified oligonucleotides in infectious diseases
CA2449802C (en) 2001-06-05 2012-02-07 Pola Chemical Industries Inc. Polypeptide for unstabilizing a protein in a cell under aerobic conditions and dna encoding the same
US7153954B2 (en) * 2001-07-12 2006-12-26 Santaris Pharma A/S Method for preparation of LNA phosphoramidites
ATE287413T1 (de) 2001-07-12 2005-02-15 Santaris Pharma As Verfahren zur herstellung des lna phosphoramidite
PT2264172T (pt) 2002-04-05 2017-12-06 Roche Innovation Ct Copenhagen As Compostos oligoméricos para a modulação da expressão do hif-1α.
DE60315444T2 (de) 2002-05-08 2008-04-30 Santaris Pharma A/S Synthese von locked nucleic acid-derivaten
AU2003291678B2 (en) 2002-11-01 2009-01-15 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
DK2284269T3 (en) 2002-11-18 2017-10-23 Roche Innovation Ct Copenhagen As Antisense design
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
DE602004022020D1 (de) 2003-02-10 2009-08-27 Santaris Pharma As Oligomere verbindungen zur modulation der expression von survivin
EP1592795A2 (de) 2003-02-10 2005-11-09 Santaris Pharma A/S Oligomere verbindungen zur modulation der expression von ras
DK1833840T3 (da) * 2004-11-09 2010-10-18 Santaris Pharma As Micromirs

Also Published As

Publication number Publication date
US7939507B2 (en) 2011-05-10
IL183054A0 (en) 2007-09-20
CA2587173A1 (en) 2006-05-18
NO20072933L (no) 2007-06-08
MX2007005558A (es) 2008-01-31
NZ555644A (en) 2009-04-30
JP2008518608A (ja) 2008-06-05
DE602005022768D1 (de) 2010-09-16
DK1833840T3 (da) 2010-10-18
JP2011229540A (ja) 2011-11-17
BRPI0515726A8 (pt) 2017-09-12
EA200701033A1 (ru) 2007-12-28
JP4825807B2 (ja) 2011-11-30
WO2006050734A2 (en) 2006-05-18
AU2005304112B2 (en) 2009-06-04
US20060252721A1 (en) 2006-11-09
US20110183931A1 (en) 2011-07-28
AU2005304112A1 (en) 2006-05-18
JP2014098027A (ja) 2014-05-29
EP1833840B9 (de) 2010-11-10
US7589190B2 (en) 2009-09-15
EP1833840B1 (de) 2010-08-04
KR20070094891A (ko) 2007-09-27
KR101176245B1 (ko) 2012-08-22
EP1833840A2 (de) 2007-09-19
EA014097B1 (ru) 2010-08-30
US20090286859A1 (en) 2009-11-19
US8410071B2 (en) 2013-04-02
BRPI0515726A (pt) 2008-08-05
NO341878B1 (no) 2018-02-12
WO2006050734A3 (en) 2006-08-03
CA2587173C (en) 2016-09-06

Similar Documents

Publication Publication Date Title
ATE476441T1 (de) Wirksame lna-oligonukleotide zur inhibierung von hif-1a
ATE418992T1 (de) Verwendung von tgf-beta2 antisense oligonukleotiden
EP1578933A4 (de) ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-INHIBITION DER ANGIOGENESE
UA125963C2 (uk) Олігонуклеотид для індукції батьківської експресії ube3a
WO2004035765A3 (en) Double-stranded rna structures and constructs, and methods for generating and using the same
ATE477337T1 (de) Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
EP2002018A4 (de) Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion
RU2017127609A (ru) Антисмысловые олигомеры тау-белка и их применение
BRPI0418104A (pt) compostos oligoméricos para a modulação de bcl-2
NZ700561A (en) Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders
WO2009017803A8 (en) Antisense microrna and uses therefor
NZ603606A (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
ATE460481T1 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
WO2004011624A3 (en) Double stranded rna structures and constructs, and methods for generating and using the same
WO2007030691A3 (en) Antisense antiviral compound and method for treating picornavirus infection
WO2008132234A4 (en) Rna antagonist compounds for the modulation of beta-catenin
MXPA05011221A (es) Composiciones y metodos para la inhibicion de angiopoyetina 1 y 2 y su receptor tie2 por arnsi.
Govan et al. Optically triggered immune response through photocaged oligonucleotides
PE20212248A1 (es) Molecula oligomerica de acido nucleico y uso de esta
HK1113318A1 (en) Oligonucleotide and compositions comprising the same for treating b cell neoplasm
UA93188C2 (ru) Эффективные олигонуклеотиды lna для ингибирования экспрессии hif-1a
Yamada et al. Remarkable stabilization of antiparallel DNA triplexes by strong stacking effects of consecutively modified nucleobases containing thiocarbonyl groups
Langkjær et al. Watson–Crick hydrogen bonding of unlocked nucleic acids
Torrence et al. Evaluation of synthetic oligonucleotides as inhibitors of West Nile virus replication
ATE555201T1 (de) Verwendung von sirna zur abschaffung der expression von eif-5a1 in der behandlung von glaukoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties